It is non-purine selective inhibitor of xanthine oxidase, thereby reducing production of Uric Acid. Approved by USFDA & EMA for the treatment of Hyperuricemia & Gout. It is more effective than fixed dose allopurinol (300mg) in lowering serum level uric acid concentration. No dose adjustment is necessary when administering febuxostat in patients with mild to moderate renal hepatic impairment Safe & well tolerated.

• Excellent penetration in respiratory tissue & bile.
• Total eradication of pathogens.
• Injectable efficacy in oral therapy.
• Quicker fever resolution / infection control.